Free Trial
NASDAQ:INBX

Inhibrx (INBX) Stock Price, News & Analysis

Inhibrx logo
$14.00 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$14.00 0.00 (0.00%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Inhibrx Stock (NASDAQ:INBX)

Key Stats

Today's Range
$13.86
$14.34
50-Day Range
$12.24
$14.98
52-Week Range
$10.80
$35.42
Volume
49,012 shs
Average Volume
218,030 shs
Market Capitalization
$202.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Remove Ads

Inhibrx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

INBX MarketRank™: 

Inhibrx scored higher than 29% of companies evaluated by MarketBeat, and ranked 768th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Percentage of Shares Shorted

    11.96% of the float of Inhibrx has been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibrx has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inhibrx has recently decreased by 7.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Inhibrx does not currently pay a dividend.

  • Dividend Growth

    Inhibrx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.96% of the float of Inhibrx has been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibrx has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inhibrx has recently decreased by 7.03%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Inhibrx has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Inhibrx this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Inhibrx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Inhibrx's insider trading history.
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

INBX Stock News Headlines

Lying in hospital… staring at the light
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
Inhibrx Biosciences Inc (INBX) Gets a Hold from JMP Securities
See More Headlines

INBX Stock Analysis - Frequently Asked Questions

Inhibrx's stock was trading at $15.40 on January 1st, 2025. Since then, INBX shares have decreased by 9.9% and is now trading at $13.87.
View the best growth stocks for 2025 here
.

Inhibrx, Inc. (NASDAQ:INBX) released its quarterly earnings results on Monday, March, 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.88) by $0.21. The business earned $0.10 million during the quarter.

Inhibrx (INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Top institutional shareholders of Inhibrx include Sanofi (8.00%), HighTower Advisors LLC (5.40%), Walleye Capital LLC (4.01%) and Slotnik Capital LLC (2.68%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Global Investors Lp Viking, Jon Faiz Kayyem and Kristiina Md Vuori.
View institutional ownership trends
.

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Shopify (SHOP), Zoom Video Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA).

Company Calendar

Last Earnings
3/17/2025
Today
3/19/2025
Next Earnings (Estimated)
3/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INBX
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-154,960,000.00
Pretax Margin
110,409.73%

Debt

Sales & Book Value

Annual Sales
$1.57 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
11,262,000
Market Cap
$202.66 million
Optionable
Optionable
Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:INBX) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners